News | April 27, 2024
AstraZeneca 1Q 2024 revenue up 19% to US$ 12,679 million
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Application based on results from the TROPION-Breast01 Phase III trial
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
Combination shows consistent benefit across prespecified post-progression outcomes
To accelerate the development of next-generation radioconjugates to treat cancer
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
The validations confirm the completion of the applications and commence the scientific review process
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Subscribe To Our Newsletter & Stay Updated
